+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cutaneous T-Cell-Lymphoma Market (CTCL) by Indication (Mycosis Fungoides, Sézary Syndrome), Treatment (Biological Therapies, Phototherapy, Radiation Therapy), Product, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5977847
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cutaneous T-Cell-Lymphoma Market grew from USD 416.77 million in 2023 to USD 432.44 million in 2024. It is expected to continue growing at a CAGR of 3.91%, reaching USD 545.49 million by 2030.

Unlike other lymphomas, which can affect any body part, CTCL primarily affects the skin. This condition can result in various symptoms, including patches, plaques, or tumors on the skin, and sometimes, itching. The progression of CTCL is generally slow, and it can be managed but not cured with current treatments. The cause of CTCL is poorly understood and is a relatively rare form of lymphoma. Treatment options may include skin creams, light therapy, radiation therapy, and, in more severe cases, chemotherapy or biological therapies. They are increasing prevalence and awareness toward cutaneous t-cell lymphoma and supportive regulatory policies for fast-track approval processes and incentives fuelling demand for targeted therapies and treatments specific to CTCL. However, the high cost of treatment, the possibility of misdiagnosis or delayed diagnosis, and technical and performance issues associated with treatments can deter market adoption. Nevertheless, expanding clinical trials and collaborative research initiatives and increasing developments in targeted therapies and immunotherapies are expected to create several opportunities to expand the market for specialized therapeutic solutions for CTCL.

Regional Insights

The Americas has a robust healthcare system with advanced treatments available for CTCL. Frequent research initiatives and substantial investment in healthcare allow for early diagnosis and innovative therapies. Patients benefit from state-of-the-art clinical trials, many of which are supported by government bodies, including the NIH, and private sector investments. Pharmaceutical companies and research institutes in the Americas are increasingly filing patents on new drugs and therapies for CTCL. European countries benefit from a cohesive regulatory framework that facilitates widespread access to new treatments across the continent. With a higher prevalence of CTCL noted in some regions, there is a concerted effort towards specialized healthcare services for CTCL patients. Germany, France, and the UK emphasize research and clinical trials. The European Medicines Agency (EMA) is crucial in approving and disseminating new therapies, ensuring safe and efficient patient access across member states. In the Middle East, the awareness and treatment of CTCL are growing, with countries undergoing medical research and development. Africa region faces significant hurdles concerning healthcare access and affordability, which impacts the diagnosis and treatment of CTCL. Several international and local NGOs are active in improving general healthcare conditions, which indirectly aids in increasing awareness and management of various diseases, including CTCL. Asia Pacific has seen remarkable growth in healthcare capabilities, including managing rare diseases, including CTCL. Increased healthcare expenditure and domestic pharmaceutical research are positively impacting the availability of new therapies. There has also been a notable rise in patent filing and government support for biotechnology.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Cutaneous T-Cell-Lymphoma Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing prevalence and awareness toward cutaneous t-cell lymphoma
  • Supportive regulatory policies for fast-track approval processes and incentives

Market Restraints

  • High cost of treatment, along with misdiagnosis and delayed diagnosis

Market Opportunities

  • Expansion of clinical trials and collaborative research initiatives
  • Rising developments in targeted therapies and immunotherapies

Market Challenges

  • Technical and performance issues associated with treatments

Market Segmentation Analysis

  • Indication: Burgeoning cases of mycosis fungoides allow for a range of both localized and systemic treatments
  • End-User: Evolving usage of clinics offering considerable expertise in specific treatments and personalized care for CTCL

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cutaneous T-Cell-Lymphoma Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cutaneous T-Cell-Lymphoma Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Granted Approval of Innovative Follicular Lymphoma Treatment Combination

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new treatment combination targeted at follicular lymphoma, a type of non-Hodgkin lymphoma. This decision marks a significant advancement in therapeutic options for patients suffering from this disease. The approved treatment regimen combines two drugs that have shown the potential to enhance treatment efficacy and improve patient outcomes. Accelerated approval was granted based on preliminary clinical data indicating substantial improvements in disease response compared to existing therapies. This development is considered a crucial step in the ongoing battle against lymphoma, providing patients with more effective treatment options and potentially improving their quality of life.

FDA Endorses Soquelitinib for T-Cell Lymphoma with Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to Soquelitinib, a novel therapeutic agent targeting T-cell lymphoma. This cancer affects the lymphatic system and presents primarily in the skin. This designation is pivotal as it supports the development and potential approval of Soquelitinib by providing certain benefits, including tax credits for clinical testing, exemption from FDA application fees, and seven years of market exclusivity upon approval. Orphan drug status is granted to encourage the development of treatments for rare diseases affecting fewer than 200,000 people annually in the U.S. The development of Soquelitinib by Impact Therapeutics signifies an important advancement in the options available for treating this challenging and rare form of cancer, offering hope for improved outcomes in affected patients.

Kymera Therapeutics Granted FDA Fast Track Status for Innovative CTCL Treatment

Kymera Therapeutics has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, KT-333, tailored for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). This designation is instrumental in facilitating the development and expediting the review of drugs to treat serious conditions and fill an unmet medical need. KT-333, an IRAK4 degrader, represents a significant advancement in targeted therapy, targeting the root biological mechanisms of CTCL. The Fast Track status underscores the potential of KT-333 to address critical gaps in existing treatment options for patients battling advanced stages of this debilitating disease.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cutaneous T-Cell-Lymphoma Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cutaneous T-Cell-Lymphoma Market, highlighting leading vendors and their innovative profiles. These include 4SC AG, Allos Therapeutics, Inc., Amgen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bristol Myers Squibb, Corvus Pharmaceuticals, Inc., Eisai Co., Ltd., Elorac, Inc., Helsinn Healthcare SA, Incyte Corporation, Kyowa Kirin Co., Ltd., Merck & Co. Inc., Mundipharma International Limited, PharmaMar SA, Seattle Genetics, Inc., Soligenix, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cutaneous T-Cell-Lymphoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication

  • Mycosis Fungoides
  • Sézary Syndrome

Treatment

  • Biological Therapies
  • Phototherapy
  • Radiation Therapy
  • Topical Therapies

Product

  • Imaging Technology
  • Molecular Diagnostics
  • Phototherapy Equipment

Treatment Drugs

  • Chemotherapeutics
  • Immunomodulators
  • Targeted Therapy

End-User

  • Ambulatory Surgery Centers
  • Dermatology Clinics
  • Homecare Settings
  • Hospitals
  • Research Centers

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence and awareness toward cutaneous t-cell lymphoma
5.1.1.2. Supportive regulatory policies for fast-track approval processes and incentives
5.1.2. Restraints
5.1.2.1. High cost of treatment, along with misdiagnosis and delayed diagnosis
5.1.3. Opportunities
5.1.3.1. Expansion of clinical trials and collaborative research initiatives
5.1.3.2. Rising developments in targeted therapies and immunotherapies
5.1.4. Challenges
5.1.4.1. Technical and performance issues associated with treatments
5.2. Market Segmentation Analysis
5.2.1. Indication: Burgeoning cases of mycosis fungoides allow for a range of both localized and systemic treatments
5.2.2. End-User: Evolving usage of clinics offering considerable expertise in specific treatments and personalized care for CTCL
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Cutaneous T-Cell-Lymphoma Market, by Indication
6.1. Introduction
6.2. Mycosis Fungoides
6.3. Sézary Syndrome
7. Cutaneous T-Cell-Lymphoma Market, by Treatment
7.1. Introduction
7.2. Biological Therapies
7.3. Phototherapy
7.4. Radiation Therapy
7.5. Topical Therapies
8. Cutaneous T-Cell-Lymphoma Market, by Product
8.1. Introduction
8.2. Imaging Technology
8.3. Molecular Diagnostics
8.4. Phototherapy Equipment
8.5. Treatment Drugs
9. Cutaneous T-Cell-Lymphoma Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgery Centers
9.3. Dermatology Clinics
9.4. Homecare Settings
9.5. Hospitals
9.6. Research Centers
10. Americas Cutaneous T-Cell-Lymphoma Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cutaneous T-Cell-Lymphoma Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cutaneous T-Cell-Lymphoma Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. FDA Granted Approval of Innovative Follicular Lymphoma Treatment Combination
13.3.2. FDA Endorses Soquelitinib for T-Cell Lymphoma with Orphan Drug Designation
13.3.3. Kymera Therapeutics Granted FDA Fast Track Status for Innovative CTCL Treatment
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET RESEARCH PROCESS
FIGURE 2. CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CUTANEOUS T-CELL-LYMPHOMA MARKET DYNAMICS
FIGURE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CUTANEOUS T-CELL-LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. CUTANEOUS T-CELL-LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY BIOLOGICAL THERAPIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY BIOLOGICAL THERAPIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TOPICAL THERAPIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TOPICAL THERAPIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY EQUIPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY EQUIPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY CHEMOTHERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY CHEMOTHERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 85. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 88. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 89. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 90. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 91. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 92. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 93. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 94. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 95. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 98. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 99. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 100. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 101. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 102. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 103. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 104. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 115. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 116. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 128. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 137. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 138. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 139. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 142. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 143. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 144. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 145. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 146. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 147. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 148. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 149. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 152. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 153. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 154. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 155. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 156. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 157. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 158. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 167. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 168. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 169. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 172. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 173. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 174. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 175. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 176. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 177. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 178. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 187. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 188. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 197. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 198. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 207. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 208. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 217. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 218. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 227. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 228. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 229. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 232. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 233. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 234. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 235. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 236. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 237. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 238. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 247. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 248. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 261. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 264. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 265. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 266. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 267. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 268. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 269. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 270. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 271. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 274. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 275. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 276. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 277. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 278. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 279. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 280. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 281. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 284. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 285. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 286. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 287. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 288. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 289. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 290. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 291. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 294. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 295. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 296. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 297. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 298. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 299. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 300. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 301. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 302. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 303. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 304. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 305. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 306. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 307. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 308. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 309. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 310. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 311. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 312. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 313. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 314. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 319. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 320. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 321. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 322. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 323. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 324. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 325. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 326. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 327. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2023 (USD MILLION)
TABLE 328. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2024-2030 (USD MILLION)
TABLE 329. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 330. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 331. NETHERLANDS CUTANEOUS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4SC AG
  • Allos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bristol Myers Squibb
  • Corvus Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Elorac, Inc.
  • Helsinn Healthcare SA
  • Incyte Corporation
  • Kyowa Kirin Co., Ltd.
  • Merck & Co. Inc.
  • Mundipharma International Limited
  • PharmaMar SA
  • Seattle Genetics, Inc.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 432.44 Million
Forecasted Market Value ( USD ) by 2030 $ 545.49 Million
Compound Annual Growth Rate3.9%
Regions CoveredGlobal

Related Topics

Related Reports

Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 139 Pages
  • Global
From
Cutaneous T-Cell Lymphoma - Market Insight, Epidemiology And Market Forecast - 2034 - Product Image

Cutaneous T-Cell Lymphoma - Market Insight, Epidemiology And Market Forecast - 2034

  • Drug Pipelines
  • 210 Pages
  • Global
From
T-Cell Lymphoma Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

T-Cell Lymphoma Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global T-Cell Lymphoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Global T-Cell Lymphoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 132 Pages
  • Global
From
Global T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Global T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 208 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.